Health Care/Hospital
International Self-Care Day: Dimora Medical Highlights Wound Care as an Essential Part of Everyday Self-Care
NEW YORK, July 24, 2026 /PRNewswire/ -- As International Self-Care Day draws attention to the importance of maintaining health around the clock, the concept of 24/7 self-care continues to gain momentum among consumers seeking more proactive approaches to everyday well-being. While nutrition, exer...
2026-07-25 01:50
3413
Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a ...
2026-07-24 08:02
3333
Fapon Showcases AI-Engineered Enzymes and Alzheimer's Solutions at ADLM 2026, Reinforcing North American Commitment
ANAHEIM, Calif., July 23, 2026 /PRNewswire/ -- Fapon, a trusted global IVD provider with deepening roots in North America, will exhibit at ADLM 2026 from July 26 to 30 in Anaheim, California. The company will introduce novel AI-engineered enzymes for molecular diagnostics alongside a full suite o...
2026-07-24 01:10
1845
AH-008 Achieves Key Clinical Milestone with Successful First Subject First Dose (FSFD) in Phase I Study for Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
TAIPEI, July 23, 2026 /PRNewswire/ -- AnHorn Medicines today announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). This m...
2026-07-23 22:00
1826
Zhongchao Inc. Announces $5.0 Million Registered Direct Offering
SHANGHAI, July 23, 2026 /PRNewswire/ -- Zhongchao Inc ("Zhongchao" or the "Company") (NASDAQ: ZCMD), today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of4,545,455 of the Company's Class A Ordinary Shares, par value $0...
2026-07-23 21:00
2260
Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH
BEIJING, July 23, 2026 /PRNewswire/ -- Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has receivedmarketing approval from the National Medical Products Administration of China (NMPA) for t...
2026-07-23 14:08
883
Samsung Biologics Reports Second Quarter 2026 Financial Results
* Recorded Q2'26 revenue of KRW 1,321 billion and operating profit of KRW 586 billion * Delivered stable business performance through continued disciplined execution * Expanded global presence while advancing innovation and future growth initiatives INCHEON, South Korea, July 23, 2026 /PRNe...
2026-07-23 07:03
2501
HKEY-AI4AI-Atlas™ 1.0: HKeyBio Uses AI to Curate Autoimmune Model Datasets
HKEY-AI4AI-Atlas™ 1.0 uses AI-assisted dataset curation to support model selection, endpoint design and cross-species interpretation BOSTON and SUZHOU, China, July 22, 2026 /PRNewswire/ -- HKeyBio is building HKEY-AI4AI-Atlas™ 1.0, its AI-Assisted Autoimmune Model Data Atlas. The internal capabi...
2026-07-22 21:16
2127
Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management
* AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class,brain -penetrant, non-opioid solution for pain management. * Superior Therapeutic Profile: In preclinical studies, ISM9528 demonstrated super...
2026-07-22 21:00
3279
China Pharma Holdings, Inc. Comments on Unusual Market Activity
HAIKOU, China, July 21, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July...
2026-07-22 04:00
2939
The Second Battlefield for Solid Tumor CAR-T: A Global Race in the Intracranial Arena -- Who Is Leading?
T-MAXIMUM PHARMACEUTICAL Inc's Universal CAR-T First-in-Human Data to Debut at the World Conference on Lung Cancer BEIJING, July 21, 2026 /PRNewswire/ -- Recently, the 2026 World Conference on Lung Cancer (WCLC) released a set of abstracts that drew notable industry attention: preliminary first-...
2026-07-21 20:30
2560
Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia
SHANGHAI, July 21, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the first participant has been randomized and dosed in the global Phase IIb multi-regional clinical trial of...
2026-07-21 19:00
2097
Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization
Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline KYOTO, Japan, July 21, 2026 /PRNewswire/ -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicin...
2026-07-21 12:00
1965
ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation
SHANGHAI, July 20, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present the latest clinical study results of its novel Nectin‑4‑targeting ADC, 9MW2821, for triple‑negative breast cancer in an oral ...
2026-07-21 11:50
2153
SuanNutra, Parent Company of Monteloeder and a Carbyne Equity Partners Portfolio Company, Expands Product Portfolio with Specialty Natural Ingredients Businesses from IFF
MADRID, July 20, 2026 /PRNewswire/ -- SuanNutra, the global science-backed ingredients group, today announced it has signed an agreement to acquire a portfolio of specialty natural ingredients businesses from IFF (NYSE: IFF). The transaction, backed by SuanNutra's majority shareholder Carbyne Equ...
2026-07-21 07:30
5666
PharmaBlock Convenes Global Industry Leaders in Zurich to Advance Green Chemistry for Sustainable Pharmaceutical Manufacturing
ZURICH, July 20, 2026 /PRNewswire/ -- As Europe experienced one of its hottest Junes on record, with prolonged heatwaves reinforcing the urgency of climate action, leaders from the pharmaceutical industry and academia gathered in Zurich for thePharmaBlock's 3rd Green Chemistry Symposium (GCS) to ...
2026-07-20 20:00
3730
Fostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industry
SHANGHAI, July 20, 2026 /PRNewswire/ -- Following the landmark success of CPHI & PMEC China in June 2026, which welcomed an unprecedented gathering of industry professionals and fostered pivotal connections across the pharmaceutical supply chain, attention now shifts to South China. Building on ...
2026-07-20 13:47
1643
Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC
HONG KONG, July 20, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (ADC), AK146D1, in combi...
2026-07-20 13:32
2371
Neuronata-R retains conditional approval in South Korea
South Korea's Ministry of Food and Drug Safety (MFDS) updates the stem cell therapy's approval in May 2026 — as the developer works to resume supply and build a U.S. research base SEOUL, South Korea, July 19, 2026 /PRNewswire/ -- Patients with amyotrophic lateral sclerosis (ALS) in South Korea w...
2026-07-20 07:00
1904
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
* Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at CHF 44.31 per share, representing an equity value of approximately CHF 1.46 billion. * Strong transaction support, with a unanimous ...
2026-07-20 06:43
3806
Week's Top Stories
Most Reposted
Visa and Lianlian Advance Trusted B2B Agentic Commerce Through LoopXPay's First Live B2B Agentic Transaction
[Picked up by 318 media titles]
2026-07-24 12:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 297 media titles]
2026-07-20 15:00
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
[Picked up by 295 media titles]
2026-07-23 16:00
Phuket Marriott Resort & Spa, Merlin Beach Elevates Guest Experience with New Dining and Family Facilities
[Picked up by 293 media titles]
2026-07-24 18:32
Courtyard by Marriott Phuket, Patong Beach Wins TripAdvisor Best of the Best Award
[Picked up by 290 media titles]
2026-07-24 16:25
Most Read
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
2026-07-20 15:00
17768
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
2026-07-23 16:00
8879
Omni HR Launches Native MCP Integration, Connecting AI Assistants to Live HR Data
2026-07-20 11:00
8801
